| 1 |
34246414 | SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. | 2022 Jan 20 |
1 |
| 2 |
35060381 | Structural Insights into the Cofactor Role of Heparin/Heparan Sulfate in Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II. | 2022 Feb 14 |
2 |
| 3 |
33173010 | Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. | 2021 Jan 13 |
2 |
| 4 |
33514685 | Engaging the spikes: heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection. | 2021 Jan 29 |
1 |
| 5 |
33851732 | Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19. | 2021 Sep |
2 |
| 6 |
33915212 | Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. | 2021 Jul 31 |
1 |
| 7 |
34179075 | Heparan Sulfate Facilitates Spike Protein-Mediated SARS-CoV-2 Host Cell Invasion and Contributes to Increased Infection of SARS-CoV-2 G614 Mutant and in Lung Cancer. | 2021 |
2 |
| 8 |
34196550 | Regulation Mechanism for the Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II. | 2021 Jul 15 |
2 |
| 9 |
32577638 | Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. | 2020 Jul 28 |
2 |
| 10 |
32699847 | Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. | 2020 Sep 18 |
2 |
| 11 |
32699853 | SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. | 2020 Jul 14 |
2 |
| 12 |
32970989 | SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. | 2020 Nov 12 |
2 |
| 13 |
32992731 | Impact of Comorbidities on SARS-CoV-2 Viral Entry-Related Genes. | 2020 Sep 25 |
2 |
| 14 |
33298900 | Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. | 2020 Nov 4 |
2 |